<?xml version="1.0" encoding="UTF-8"?>
<wcm:root xmlns:wcm="http://www.stellent.com/wcm-data/ns/8.0.0">
  <wcm:element name="MainContent">&lt;table cellspacing="0" summary="meeting date, time, location and sponsoring Center" cellpadding="5"&gt;&lt;tbody&gt;&lt;tr valign="top" align="left" bgcolor="#cccccc"&gt;&lt;th&gt;Center&lt;/th&gt;&lt;th&gt;Date&lt;/th&gt;&lt;th&gt;Time&lt;/th&gt;&lt;th&gt;Location&lt;/th&gt;&lt;/tr&gt;&lt;tr valign="top" align="left"&gt;&lt;td&gt;CBER&lt;/td&gt;&lt;td&gt;March 18, 2009&lt;/td&gt;&lt;td&gt;8 am to approximately 12:30 pm.&lt;/td&gt;&lt;td&gt;Food and Drug Administration, Center for Drug Evaluation and Research, Advisory Committee Conference Room, Room 1066, 5630 Fishers Lane, Rockville, MD&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;h4&gt;Agenda&lt;/h4&gt;&lt;p&gt;On March 18, 2009, the committee will discuss 1) a proposed change of potency assay for short ragweed pollen and cat allergen extracts from radial immunodiffusion assay to an enzyme-linked immunosorbent assay and 2) structured product labeling. The committee will also receive an update on research programs in the Laboratory of Immunobiochemistry, Division of Bacterial, Parasitic and Allergenic Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, FDA.&lt;/p&gt;&lt;h4&gt;&lt;a href="[!--$ssLink(&amp;quot;ucm129361.htm&amp;quot;)--]"&gt;Meeting Materials&lt;/a&gt;&lt;/h4&gt;&lt;p&gt;&lt;br /&gt;&amp;nbsp;&lt;/p&gt;&lt;h4&gt;Public Participation Information&lt;/h4&gt;&lt;p&gt;Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.&lt;/p&gt;&lt;ul&gt;&lt;li&gt;Written submissions may be made to the contact person on or before March 11, 2009.&lt;/li&gt;&lt;li&gt;Oral presentations from the public will be scheduled between will be scheduled between approximately 10:45 am and 11:45 am. Those desiring to make formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of propose d participants, and an indication of the approximate time requested to make their presentations on or before March 3, 2009. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by March 4, 2009 .&lt;/li&gt;&lt;/ul&gt;&lt;h4&gt;Contact Information&lt;/h4&gt;&lt;ul&gt;&lt;li&gt;Gail Dapolito&lt;br /&gt;1401 Rockville Pike, HFM-71, Rockville, MD 20852&lt;br /&gt;301-827-0314&lt;br /&gt;FAX: 301-827-0294&lt;br /&gt;e-mail: Gail Dapolito@fda.hhs.gov&lt;/li&gt;&lt;li&gt;FDA Advisory Committee Information Line&lt;br /&gt;1-800-741-8138&lt;br /&gt;(301-443-0572 in the Washington, DC, area)&lt;br /&gt;code 3014512388&lt;br /&gt;Please call the Information Line for up-to-date information on this meeting.&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA&amp;rsquo;s Web site after the meeting.&lt;/p&gt;&lt;p&gt;A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the agency&amp;rsquo;s Web site and call the appropriate advisory committee hot line/phone line to learn about possible modifications before coming to the meeting.&lt;/p&gt;&lt;p&gt;Persons attending FDA&amp;rsquo;s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Gail Dapolito or Jane Brown at least 7 days in advance of the meeting. FDA is committed to the orderly conduct of its advisory committee meetings. Please &lt;a href="[!--$ssNodeLink(&amp;quot;1840&amp;quot;)--]"&gt;visit our Web site&lt;/a&gt; for procedures on public conduct during advisory committee meetings.&lt;/p&gt;&lt;p&gt;Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).&lt;/p&gt;</wcm:element>
<wcm:element name="MainList1"></wcm:element>
  <wcm:element name="MainList2"></wcm:element>
  <wcm:element name="MainList3"></wcm:element>
</wcm:root>
